Fortress Biotech Sells PRV for $205M After ZYCUBO Approval

Cyprium Therapeutics (Fortress Biotech subsidiary) just signed a deal to sell its Rare Pediatric Disease Priority Review Voucher for $205M after FDA approval of ZYCUBO for Menkes disease.